Skip to main content

Table 1 Baseline characteristics of 1986 patients with breast cancer

From: Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions

  No. (%) No PMRT
(n = 1521)
PMRT
(n = 465)
p
Entire Cohort
(N = 1986)
Treatment era     <  0.001
 1/2000–12/2009 959 (48.3) 807 (53.1) 152 (32.7)  
 1/2010–12/2014 1027 (51.7) 714 (46.9) 313 (67.3)  
Age (years)     <  0.001
  ≤ 40 349 (17.7) 221 (14.5) 128 (27.5)  
  > 40 1637 (82.3) 1300 (85.5) 337 (72.5)  
Tumor location     0.249
 Inner quadrant 439 (22.1) 346 (22.7) 93 (20.0)  
 Other quadrants 1526 (76.8) 1162 (76.4) 364 (78.3)  
 Unknown 21 (1.1) 13 (0.9) 8 (1.7)  
Stage (AJCC 8th ed.)     <  0.001
 IA 621 (31.3) 508 (33.4) 113 (24.3)  
 IB- IIA 985 (49.6) 760 (50.0) 225 (48.4)  
 IIB- IIIA 380 (19.1) 253 (16.6) 127 (27.3)  
No. of positive nodes     <  0.001
 1 1023 (51.5) 878 (57.7) 145 (31.2)  
 2–3 963 (48.5) 643 (42.3) 320 (68.8)  
No. of nodes dissected     0.002
  < 10 124 (6.2) 80 (5.3) 44 (9.5)  
  ≥ 10 1862 (93.8) 1441 (94.7) 421 (90.5)  
Lympho-vascular invasion     <  0.001
 Yes 279 (14.0) 184 (12.1) 95 (20.4)  
 No 1704 (85.8) 1337 (87.9) 367 (78.9)  
 Unknown 3 (0.2) 0 (0) 3 (0.7)  
Histological grade     0.004
 I 76 (3.8) 69 (4.5) 7 (1.5)  
 II 1309 (65.9) 1008 (66.3) 301 (64.7)  
 III 601 (30.3) 444 (29.2) 157 (33.8)  
T stage     0.001
 T1 953 (48.0) 762 (50.1) 191 (41.1)  
 T2 1033 (52.0) 759 (49.9) 274 (58.9)  
Estrogen receptor     <  0.001
 Negative 509 (25.6) 358 (23.5) 151 (32.5)  
 Positive 1477 (74.4) 1163 (76.5) 314 (67.5)  
Progesterone receptor     <  0.001
 Negative 542 (27.6) 369 (24.3) 173 (37.2)  
 Positive 1444 (72.4) 1152 (75.7) 292 (62.8)  
HER2 status     0.002
 Negative 1804 (90.8) 1410 (92.7) 394 (84.7)  
 Positive 182 (9.2) 111 (7.2) 71 (15.3)  
  1. Abbreviations: PMRT post-mastectomy radiotherapy, AJCC 8th ed. American Joint Committee on Cancer Staging Manual, 8th edition